Latest1 information on COVID-19
©2022 Stanford Medicine
Evaluation of Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Cancer
Not Recruiting
Trial ID: NCT00238602
Purpose
This study has two primary objectives. The first objective is to determine the maximal
tolerated dose (MTD) that can be delivered with stereotactic radiosurgery in patients with
inoperable malignant lung tumors. Once the MTD is established, the second objective is to
determine the efficacy of radiosurgical ablation of lung tumors in terms of symptoms and
radiographic responses.
Official Title
Evaluation of the Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Tumors - A Phase I/II Study
Stanford Investigator(s)
Billy W Loo, Jr, MD PhD FASTRO FACR
Professor of Radiation Oncology (Radiation Therapy)
Heather Wakelee
Professor of Medicine (Oncology)
Quynh-Thu Le, MD
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Eligibility
Inclusion Criteria:1.Lung tumor >= 5.0 cm.
2.Age > 18 years,
3.Histologic confirmation of malignancy (primary lung or metastatic tumor)
4.Deemed unresectable either by radiographic criteria (such as direct invasion of the
mediastinum, heart, great vessels, or trachea), by virtue of excessive risk to patient,
patient refusal to undergo surgery, or prior operative findings.
5.Performance status of 0-2 by Eastern Clinical Oncology Group criteria Exclusion
Criteria:1. No chemotherapy within 2 weeks of radiation treatment.
2. Refusal to sign informed consent.
3. Refusal to take a pregnancy test prior to treatment if the patient is a woman with child
bearing potential.
Intervention(s):
procedure: Stereotactic radiosurgery
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Lisa Zhou
6507364112